7 results
2.1 Primary objectiveTo assess the rate of no progression (NPR) at 8 weeks following treatment with the combination of gefitinib and fulvestrant in EGFR mutated patients who failed previous treatment with reversible EGFR TKI*s (gefitinib or…
Primary objective:Non-invasively determining the 11C-erlotinib brain uptake in DIPG patients by PET imaging.Secondary objective:Determining the EGFR expression in DIPG
Primary• To evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-…
The aim of the study is: to investigate the effect of DCS on the physiological and subjective correlates reflecting conditioned sexual response and subsequent extinction thereof. Hypothesis: We hypothesize that administration of DCS after an…
The primary objective of this study is to evaluate the disease control rate (DCR; confirmed complete response (CR) or partial response (PR), or stable disease (SD)) of gefitinib using Response Evaluation Criteria in Solid Tumours (RECIST) version 1.…
The aim of the study is: to investigate the effect of DCS on the physiological and subjective correlates reflecting conditioned sexual response, and sexual memory formation. Hypothesis: We hypothesize that administration of DCS after a classical…
Primary objectives: 1) Phase Ib: To estimate the MTD or RP2D of INC280 in combination with gefitinib in NSCLC patients who have c-MET dysregulation. 2) Phase II: To estimate overall clinical activity of INC280 in combination with gefitinib in NSCLC…